Search results
30 sie 2021 · Hepatitis E is a liver disease caused by hepatitis E virus (HEV). 1 It is the fifth known form of hepatitis among humans and is the one of the common causes of jaundice and acute hepatitis 2 that leads to significant human morbidity and mortality.
The overall goal of the Action plan is the elimination of viral hepatitis as a public health threat in the European Region by 2030, by reducing morbidity and mortality due to viral hepatitis and its complications, and ensuring equitable access to recommended prevention, testing, care and treatment services for all.
20 lip 2023 · Español. Key facts. Hepatitis E is an inflammation of the liver caused by infection with the hepatitis E virus (HEV). Every year there are an estimated 20 million HEV infections worldwide, leading to an estimated 3.3 million symptomatic cases of hepatitis E.
30 kwi 2018 · As a cause of significant morbidity and mortality, infection with hepatitis E virus (HEV) represents an important global public health problem. The European Association for the Study of Liver (EASL) invited a panel of experts in the field to develop Clinical Practice Guidelines (CPGs) with a particular focus on HEV geno-type (gt) 3.
As a cause of significant morbidity and mortality, infection with hepatitis E virus (HEV) represents an important global public health problem. The European Association for the Study of Liver (EASL) invited a panel of experts in the field to develop Clinical Practice Guidelines (CPGs) with a particular focus on HEV genotype (gt) 3.
Options for national testing and surveillance for hepatitis E virus in the EU/EEA – Operational guidance. Stockholm: ECDC; 2019. Stockholm, September 2019. ISBN: 978-92-9498-375-6 DOI: 10.2900/417723. Catalogue number: TQ-04-19-540-EN-N. European Centre for Disease Prevention and Control, 2019. Cover picture: © Ami Images/Science Photo Library.
12 cze 2023 · Hepatitis E virus (HEV) is the most common cause of acute hepatitis. While symptoms are generally mild and resolve within weeks, some populations (e.g., pregnant women, immunocompromised adults) are at high-risk of severe HEV-related morbidity and mortality.
